Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680912 | 0.77 | BACE1 (0.44) | NOS3NOS1NOS2BACE1KDM4E | |
| SCHEMBL30680916 | 0.74 | ALDH1A1 (0.49) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL11465342 | 0.71 | NOS2 (0.39) | NOS3NOS1NOS2BACE1MCHR1 | |
| SCHEMBL18340950 | 0.66 | BACE1 (0.48) | NOS3NOS1NOS2BACE1KDM4E | |
| SCHEMBL21223738 | 0.65 | BACE1 (0.39) | NOS3NOS1NOS2BACE1TBK1 | |
| SCHEMBL28303965 | 0.65 | NOS2 (0.55) | NOS3NOS1NOS2ALDH1A1KMT2A | |
| SCHEMBL29698778 | 0.65 | BACE1 (0.39) | NOS3NOS1NOS2BACE1TBK1 | |
| SCHEMBL9378099 | 0.63 | LMNA (0.45) | NOS3NOS1NOS2BACE1KDM4E | |
| SCHEMBL27965813 | 0.62 | HRH4 (0.34) | NOS3NOS1NOS2BACE1KDM4E | |
| SCHEMBL7505266 | 0.62 | KMT2A (0.58) | NOS3NOS1NOS2BACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322779-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-12 | — | — | US | disclosed |
| EP-4208166-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022049521-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2768506-A2 | COMPOUNDS AND METHODS FOR ENHANCING INNATE IMMUNE RESPONSES | GlaxoSmithKline LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059559-A2 | COMPOUNDS AND METHODS FOR ENHANCING INNATE IMMUNE RESPONSES | GLAXOSMITHKLINE LLC (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322779-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | IFNAR1, IFNG, EIF2AK2 | NOS3 1533/4885NOS1 1560/4885NOS2 450/4885 |
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | MYD88, IRF3, MAVS | NOS3 982/4885NOS1 1193/4885NOS2 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.